穩定性同位素標識化合物的全球市場:成長，趨勢，預測(2020年∼2025年)

全球穩定性同位素標識化合物市場在2020年∼2025年間預計將以約3.3％的年複合成長率成長。市場成長的主要原因，是癌症的發生率增加。根據國立衛生研究所(NIH)，2018年，美國估計檢出173萬5,350件新的癌症病例，60萬9,640人死亡。再加上生物科技及製藥公司的研究開發計劃的投資增加，推動市場成長。然而，同位素化合物的高成本是市場的主要缺點。

本報告提供全球穩定性同位素標識化合物市場的相關調查，市場機會和趨勢，成長及阻礙因素，各市場區隔和各地區的市場分析，競爭情形，主要企業的簡介等資訊。

目錄

第1章 簡介

• 調查成果
• 調查的前提條件
• 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

• 市場概要
• 市場成長要素
  • 成長的蛋白質體學研究
  • 癌症的盛行率的上升
• 阻礙市場要素
  • 熟練勞動力的缺乏
  • 穩定性同位素標識化合物的高成本
• 波特的五力分析
  • 新加入廠商的威脅
  • 買主/消費者談判力
  • 供應商談判力
  • 替代產品的威脅
  • 競爭加劇

第5章 市場區隔

• 各類型
  • 重氫
  • 碳-13
  • 氧-18
  • 其他
• 各用途
  • 研究開發
  • 臨床診斷
  • 其他
• 各地區
  • 北美
  • 歐洲
  • 亞太地區
  • 中東、非洲地區
  • 南美

第6章 競爭情形

• 企業簡介
  • PerkinElmer Inc
  • Merck KGaA
  • Cambridge Isotope Laboratories, Inc.
  • JSC Isotope.
  • Medical Isotopes, Inc.
  • Omicron Biochemicals, Inc.
  • Trace Sciences International
  • Alsachim
  • Taiyo Nippon Sanso Corporation

第7章 市場機會及未來趨勢

The Stable Isotope Labeled Compounds market is projected to grow with a CAGR of nearly 3.3% over the forecast period. The major factor attributing to the growth of the market is the increase in the incidence of cancer. According to the National Institutes of Health (NIH), in 2018, an estimated 1,735,350 new cases of cancer will be detected in the United States and 609,640 people will die from the disease. Furthermore, the growing investments in research and development programs by the biotechnology and pharmaceutical companies is boosting the market growth. However, the high cost of the isotope compounds is the major drawback of the market.

Key Market Trends

Research and Development Segment is Dominating the Stable Isotope Labeled Compounds Market.

The growth of the segment is attributed to the increase in research and development spending. Both government and major players are investing in product development. Stable isotope tracers can be safely governed simultaneously to the same subject without compromising future studies. The plasma volume which is needed from one sample to analyze the isotope enrichment is small, allowing even preterm infants to be studied. Extensive studies are going on for biological side effects and metabolic fate of the compound. The other factors that are boosting the market growth are the increasing incidence of cancer as these are majorly used in cancer diagnostics.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as the presence of key players, the high prevalence of cancer in the region, established healthcare infrastructure. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region the United States has the maximum share due to supportive healthcare policies, the high number of patients, and a developed healthcare market.

Competitive Landscape

The Stable Isotope Labeled Compounds market is moderately competitive and consists of several major players. Some of the international companies that are present in this market are PerkinElmer Inc, Merck KGaA, Cambridge Isotope Laboratories, Inc., JSC Isotope., Medical Isotopes, Inc., Omicron Biochemicals, Inc., Trace Sciences International, Alsachim, Taiyo Nippon Sanso Corporation.

Reasons to Purchase this report:

• The market estimate (ME) sheet in Excel format
• Report customization as per the client's requirements
• 3 months of analyst support

Table of Contents

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Proteomics Research
  • 4.2.2 Rising Prevalence of Cancer
• 4.3 Market Restraints
  • 4.3.1 Lack of Skilled Labour
  • 4.3.2 High Cost of Stable Isotope-Labeled Compounds
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Type
  • 5.1.1 Deuterium
  • 5.1.2 Carbon-13
  • 5.1.3 Oxygen-18
  • 5.1.4 Other Stable Isotopes
• 5.2 By Application
  • 5.2.1 Research and Development
  • 5.2.2 Clinical Diagnostics
  • 5.2.3 Other Applications
• 5.3 Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 PerkinElmer Inc
  • 6.1.2 Merck KGaA
  • 6.1.3 Cambridge Isotope Laboratories, Inc.
  • 6.1.4 JSC Isotope.
  • 6.1.5 Medical Isotopes, Inc.
  • 6.1.6 Omicron Biochemicals, Inc.
  • 6.1.7 Trace Sciences International
  • 6.1.8 Alsachim
  • 6.1.9 Taiyo Nippon Sanso Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS